Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of Novoseven.
Ménart
C
C
Cognet
V
V
Petit
P Y
PY
Massignon
D
D
Négrier
C
C
D019645:Arthroplasty, Replacement, Knee; D001323:Autoantibodies / Q000276:immunology*; D016063:Blood Loss, Surgical; D004359:Drug Therapy, Combination; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006488:Hemostasis, Surgical; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D007430:Intraoperative Care; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D001323:Autoantibodies; D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII; D015942:Factor VIIa